U.S. Physical Therapy Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
U.S. Physical Therapy wird ein jährliches Gewinn- und Umsatzwachstum von 29.4% bzw. 8.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 40.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.2% betragen.
Wichtige Informationen
29.4%
Wachstumsrate der Gewinne
40.1%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 20.9% |
Wachstumsrate der Einnahmen | 8.9% |
Zukünftige Eigenkapitalrendite | 9.2% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 21 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Shareholders Should Be Pleased With U.S. Physical Therapy, Inc.'s (NYSE:USPH) Price
Nov 09U.S. Physical Therapy (NYSE:USPH) Might Be Having Difficulty Using Its Capital Effectively
Aug 07U.S. Physical Therapy (NYSE:USPH) Has A Rock Solid Balance Sheet
Jul 17U.S. Physical Therapy, Inc.'s (NYSE:USPH) Business Is Trailing The Industry But Its Shares Aren't
Jun 04There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings
May 21U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44
May 11Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)
May 05A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)
Apr 21Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?
Apr 07U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit
Mar 04The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence
Dec 23Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching
Dec 07U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations
Oct 13Is U.S. Physical Therapy (NYSE:USPH) A Risky Investment?
Oct 13U.S. Physical Therapy (NYSE:USPH) Could Be Struggling To Allocate Capital
Sep 05Should You Think About Buying U.S. Physical Therapy, Inc. (NYSE:USPH) Now?
Aug 15Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?
Aug 01U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)
Jul 19At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?
May 07U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price
Apr 16U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet
Apr 01Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital
Mar 04U.S. Physical Therapy beats Q4 top and bottom line estimates; initiates FY23 outlook
Feb 23U.S. Physical Therapy: Needs To Illustrate Economic Reality Over Accounting Profit
Feb 12Is Now An Opportune Moment To Examine U.S. Physical Therapy, Inc. (NYSE:USPH)?
Jan 24We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt
Dec 20Here's Why We Think U.S. Physical Therapy (NYSE:USPH) Is Well Worth Watching
Dec 05U.S. Physical Therapy: Not The Most Comfortable Prospect
Nov 09Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 778 | 48 | 83 | 87 | 3 |
12/31/2025 | 726 | 61 | 70 | 85 | 6 |
12/31/2024 | 662 | 50 | 65 | 81 | 6 |
9/30/2024 | 639 | 14 | 73 | 82 | N/A |
6/30/2024 | 621 | 16 | 68 | 77 | N/A |
3/31/2024 | 606 | 18 | 66 | 75 | N/A |
12/31/2023 | 599 | 18 | 73 | 82 | N/A |
9/30/2023 | 585 | 24 | 64 | 72 | N/A |
6/30/2023 | 575 | 26 | 62 | 70 | N/A |
3/31/2023 | 564 | 28 | 50 | 58 | N/A |
12/31/2022 | 548 | 29 | 50 | 59 | N/A |
9/30/2022 | 536 | 39 | 48 | 57 | N/A |
6/30/2022 | 522 | 38 | 59 | 68 | N/A |
3/31/2022 | 509 | 37 | 61 | 70 | N/A |
12/31/2021 | 490 | 31 | 68 | 76 | N/A |
9/30/2021 | 477 | 31 | 78 | 86 | N/A |
6/30/2021 | 461 | 30 | 81 | 87 | N/A |
3/31/2021 | 418 | 32 | 95 | 101 | N/A |
12/31/2020 | 418 | 32 | 92 | 100 | N/A |
9/30/2020 | 423 | 30 | 82 | 91 | N/A |
6/30/2020 | 431 | 31 | 72 | 82 | N/A |
3/31/2020 | 473 | 29 | 55 | 65 | N/A |
12/31/2019 | 477 | 31 | 52 | 62 | N/A |
9/30/2019 | 472 | 30 | 56 | 65 | N/A |
6/30/2019 | 468 | 23 | 62 | 71 | N/A |
3/31/2019 | 457 | 18 | 63 | 71 | N/A |
12/31/2018 | 449 | 17 | 66 | 73 | N/A |
9/30/2018 | 442 | 18 | 63 | 70 | N/A |
6/30/2018 | 432 | 22 | N/A | 65 | N/A |
3/31/2018 | 421 | 21 | N/A | 58 | N/A |
12/31/2017 | 410 | 22 | N/A | 57 | N/A |
9/30/2017 | 392 | 20 | N/A | 53 | N/A |
6/30/2017 | 377 | 20 | N/A | 42 | N/A |
3/31/2017 | 363 | 21 | N/A | 51 | N/A |
12/31/2016 | 353 | 21 | N/A | 51 | N/A |
9/30/2016 | 348 | 20 | N/A | 48 | N/A |
6/30/2016 | 344 | 21 | N/A | 49 | N/A |
3/31/2016 | 337 | 21 | N/A | 49 | N/A |
12/31/2015 | 327 | 21 | N/A | 38 | N/A |
9/30/2015 | 320 | 21 | N/A | 45 | N/A |
6/30/2015 | 313 | 20 | N/A | 43 | N/A |
3/31/2015 | 308 | 20 | N/A | 45 | N/A |
12/31/2014 | 301 | 19 | N/A | 41 | N/A |
9/30/2014 | 290 | 19 | N/A | 45 | N/A |
6/30/2014 | 278 | 18 | N/A | 45 | N/A |
3/31/2014 | 267 | 18 | N/A | 44 | N/A |
12/31/2013 | 260 | 18 | N/A | 45 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: USPHDas prognostizierte Gewinnwachstum (29.4% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: USPHDie Erträge des Unternehmens (29.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: USPHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: USPHDie Einnahmen des Unternehmens (8.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: USPHDie Einnahmen des Unternehmens (8.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: USPHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.2%).